Literature DB >> 12657969

Actions of glucocorticoids and related molecules after traumatic brain injury.

Jonathan K J Rhodes1.   

Abstract

PURPOSE OF REVIEW: Despite 25 years of randomized, controlled trials, the benefit of steroid administration to patients with traumatic brain injury is unproved. Traditionally, glucocorticoids have been used empirically to reduce inflammation and edema. However, it is becoming apparent that the mechanisms by which steroid molecules might act to improve recovery after traumatic brain injury are numerous. RECENT
FINDINGS: The effects of steroid administration on the central nervous system are not uniform but depend on the population of neurons studied. Definite deleterious effects of steroid administration on neuronal survival have been described.
SUMMARY: This review discusses why glucocorticoids might be effective, the considerable laboratory evidence supporting the use of 21-aminosteroids, and the potentially harmful effects of steroid molecules on the brain. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12657969     DOI: 10.1097/00075198-200304000-00002

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  3 in total

Review 1.  [Evidence-based intensive care treatment of intracranial hypertension after traumatic brain injury].

Authors:  B H J Pannen; T Loop
Journal:  Anaesthesist       Date:  2005-02       Impact factor: 1.041

2.  Intrathecal corticoids in permanent focal cerebral ischemia in rats. Part I: a new therapeutic approach in the acute phase.

Authors:  Sophia L Goericke; Tobias Engelhorn; Michael Forsting; Ulrich Speck; Stefan Maderwald; Mark E Ladd; Arnd Doerfler
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

3.  Hemodynamic steroid responsiveness is predictive of neurological outcome after traumatic brain injury.

Authors:  Francis Bernard; Joanne Outtrim; Andrew G Lynch; David K Menon; Basil F Matta
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.